<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02742324</url>
  </required_header>
  <id_info>
    <org_study_id>RUXOPeg</org_study_id>
    <nct_id>NCT02742324</nct_id>
  </id_info>
  <brief_title>Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg</brief_title>
  <acronym>RUXOPeg</acronym>
  <official_title>Phase 1/2 Randomized Trial Combination of Ruxolitinib and Peg-interferon Alpha-2a in Patients With Primary Myelofibrosis Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1/2, open-label, multi-center, trial, aiming at to identify the most efficacious dose&#xD;
      combination that also satisfies certain safety requirements. It consists in a dose finding&#xD;
      study to assess the safety of the combination of different doses of both ruxolitinib and&#xD;
      peg-IFN alpha-2a, and a secondary randomized evaluation of the optimal doses found in the&#xD;
      first part of the study to a total maximal number of 42 evaluable patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 is a dose finding phase 1 trial that assesses the safety of the combination of&#xD;
      different doses of both ruxolitinib and peg-IFN alpha-2a&#xD;
&#xD;
      Part 2 is a phase 2 randomized evaluation of the optimal doses found in the first part of the&#xD;
      study to a total maximal number of 42 evaluable patients.&#xD;
&#xD;
      It will use the Bayesian Phase 1/2 adaptively randomized design proposed by Yuan and Yin&#xD;
      (2011) for combined drugs.The trial will examine three doses of ruxolitinib: 10, 15 and 20 mg&#xD;
      BID and three doses of the peg-IFN alpha-2a: 45, 90, and 135 mcg/week). The starting doses&#xD;
      for each drug have been selected based on prior monotherapy experience where these doses have&#xD;
      shown some degree of clinical activity as single agents and pharmacodynamic data supports the&#xD;
      activity observed. In the interest of patient safety, both of these compounds will start at&#xD;
      dose levels at or near 50% of their respective maximum tolerated doses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>study treatment efficacy/safety phase I</measure>
    <time_frame>day 45</time_frame>
    <description>Phase 1 tolerance criterion : Occurrence of dose limiting toxicities DLT within the first 45 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>study treatment efficacy/safety phase II</measure>
    <time_frame>month 6</time_frame>
    <description>Phase II Efficacy criterion: Occurrence of at least 50% reduction in spleen length as measured by palpation within the first 6 months after randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>molecular response</measure>
    <time_frame>12 months</time_frame>
    <description>molecular response measured by the evolution of JAK2V617F or CALR or MPL mutant allele burden during therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Ruxolotinib and peg-IFN alpha -2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I&#xD;
LeveL 1 Ruxolotinib 10 mg BID and peg-IFN alpha -2a 45 mcg weekly increasing doses to level 9 : Ruxolotinib 20 mg BID and peg-IFN alpha -2a 135 mcg weekly&#xD;
Phase II&#xD;
Ruxolotinib and peg-IFN alpha -2a randomized between selected doses from phase I</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolotinib</intervention_name>
    <description>Ruxolitinib is administered orally twice a day (bid) everyday in 28-day treatment cycles. The starting dose is 10 mg BID and may go up to 20 mg BID. Ruxolotinib therapy starts on Cycle 1 day 1.</description>
    <arm_group_label>Ruxolotinib and peg-IFN alpha -2a</arm_group_label>
    <other_name>Jakavi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peg-IFN alpha -2a</intervention_name>
    <description>Peg-IFN-alpha-2a is administered subcutaneously once a week. The doses tested are 45, 90 and 135 mcg/week. .Peg-IFN-alpha-2a therapy starts at Cycle 1Day 15.Of note, Peg-IFN-alpha-2a will only be started if the platelet count is ≥ 50x109/L at C1D15.</description>
    <arm_group_label>Ruxolotinib and peg-IFN alpha -2a</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients eligible for inclusion in this study have to meet all of the following criteria:&#xD;
&#xD;
          -  Age &gt; 18 years and &lt; 66 years&#xD;
&#xD;
          -  Diagnosis of primary or secondary myelofibrosis according to the 2008 World Health&#xD;
             Organization (WHO) criteria for PMF (Tefferi and Vardiman 2008) and the proposed&#xD;
             criteria for PPV-MF and PET-MF outlined by the International Working Group for&#xD;
             Myelofibrosis Research and Treatment (Barosi et al 2008)&#xD;
&#xD;
          -  Patients classified as high risk, OR intermediate risk-2, OR intermediate risk-1, as&#xD;
             defined by the International Working Group, IWG (Cervantes, et al 2009) at diagnosis&#xD;
             (or by the DIPSS (Passamonti et al. 2010) for patients assessed after diagnosis of&#xD;
             PMF)&#xD;
&#xD;
          -  Need for active therapy, defined as presence of at least one of the following:&#xD;
&#xD;
               -  symptomatic splenomegaly&#xD;
&#xD;
               -  presence of constitutional symptoms&#xD;
&#xD;
               -  anemia (Hb&lt; 10g/dl)&#xD;
&#xD;
               -  leukocytosis &gt; 25 G/l&#xD;
&#xD;
               -  thrombocytosis &gt; 400 G/l&#xD;
&#xD;
               -  Presence of JAK2V617F , Calreticulin or MPL mutations&#xD;
&#xD;
               -  Platelet counts ≥ 150 x 109/L not reached with the aide of transfusions at&#xD;
                  screening&#xD;
&#xD;
               -  Patients with ANC ≥ 1.5 x 109/L at screening without the use of G-CSF&#xD;
&#xD;
               -  Peripheral blood blast count of ≤ 10% at Screening&#xD;
&#xD;
               -  ECOG performance status of 0, 1, or 2 at Screening&#xD;
&#xD;
               -  Negative serological Hepatitis B test (i.e. HBsAg negative and anti-HBc negative,&#xD;
                  patients positive for anti-HBc may be included if PCR for HBV DNA is negative);&#xD;
                  negative testing of Hepatitis C RNA; negative HIV test within 6 weeks prior to&#xD;
                  registration.&#xD;
&#xD;
               -  Women of childbearing potential must have a negative serum (beta-human chorionic&#xD;
                  gonadotropin [beta-hCG]) or urine pregnancy test at Screening and effective&#xD;
                  contraception's method during the study and 75 days after the last dose.&#xD;
&#xD;
               -  Informed consent sign&#xD;
&#xD;
               -  Patients without Social Security coverage&#xD;
&#xD;
               -  Patient who is not included into another clinical study until 1 month after the&#xD;
                  end of this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ANC &lt; 1.5 G/l or platelets &lt; 150 G/l&#xD;
&#xD;
          -  &gt; 10% circulating blasts&#xD;
&#xD;
          -  Contra-indication to IFN alpha or to ruxolitinib&#xD;
&#xD;
          -  Patients previously treated with IFN alpha or a JAK2 inhibitor&#xD;
&#xD;
          -  Documented autoimmune disease at screening or in the medical history&#xD;
&#xD;
          -  History or presence of depression requiring treatment with antidepressant&#xD;
&#xD;
          -  Evidence of severe retinopathy (e.g. cytomegalovirus retinitis, macular degeneration)&#xD;
             or clinically relevant ophthalmological disorder (due to diabetes mellitus or&#xD;
             hypertension)&#xD;
&#xD;
          -  Thyroid dysfunction not adequately controlled&#xD;
&#xD;
          -  Women of childbearing potential who have a positive serum pregnancy test at screening&#xD;
             or who cannot or do not wish to use an effective method of contraception, during&#xD;
             treatment and for 75 days after the last dose of study drug.&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
&#xD;
          -  Patients with known active hepatitis B or C or with known HIV positivity&#xD;
&#xD;
          -  Patient with a concurrent malignancy or malignancy within 3 years of Screening, with&#xD;
             the exception of adequately treated basal or squamous cell carcinoma, non melanomatous&#xD;
             skin cancer or curatively resected cervical cancer.&#xD;
&#xD;
          -  Patient has a history of cardiac dysfunction including any of the following:&#xD;
&#xD;
               -  Myocardial infarction documented by elevated cardiac enzymes or persistent&#xD;
                  regional wall abnormalities on assessment of LVEF function&#xD;
&#xD;
               -  History of documented congestive heart failure (New York Heart Association&#xD;
                  functional classification III-IV)&#xD;
&#xD;
               -  Documented cardiomyopathy&#xD;
&#xD;
          -  Patient has active cardiac disease including any of the following:&#xD;
&#xD;
               -  Left Ventricular Ejection Fraction (LVEF) &lt; 50% as determined by Multiple Gated&#xD;
                  Acquisition (MUGA) or echocardiogram (ECHO)&#xD;
&#xD;
               -  QTc&gt; 480 msec on screening ECG (QTcF, using the Fridericia formula)&#xD;
&#xD;
               -  Angina pectoris that requires the use of anti-anginal medication&#xD;
&#xD;
               -  Ventricular arrhythmias except for benign premature ventricular contractions&#xD;
&#xD;
               -  Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled&#xD;
                  with medication&#xD;
&#xD;
               -  Conduction abnormality requiring a pacemaker&#xD;
&#xD;
               -  Valvular disease with documented compromise in cardiac function&#xD;
&#xD;
               -  Symptomatic pericarditis&#xD;
&#xD;
          -  Patients with inadequate liver or renal function at Screening as demonstrated by:&#xD;
&#xD;
               -  encephalopathy grade 1 or more, as per West Haven Criteria&#xD;
&#xD;
               -  known hepatocellular disease (e.g. active hepatitis or cirrhosis)&#xD;
&#xD;
               -  total bilirubin&gt; 2 x ULN and subsequent determination of direct bilirubin &gt; 2 x&#xD;
                  ULN alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &gt; 2 x ULN&#xD;
&#xD;
          -  MDRD-eGFR&lt; 45 mL/min/1.73m2 or on dialysis&#xD;
&#xD;
          -  Patients who currently are willing candidates for a stem cell transplantation at the&#xD;
             time of the screening assessments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Jacques KILADJIAN, MD PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FIM/GOELAMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FILO French Innovative Leukemia Organization</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.filo-leucemie.org</url>
    <description>FILO internet site</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 8, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Interferon-alfa-1b</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>e crf</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

